January 9, 2026 Sweden
BioStock: Diamyd Medical accelerates its study timeline
In an interview with BioStock, CEO Ulf Hannelius and board member Karin Rosén discuss what accelerated timeline for its phase III study DIAGNODE 3 could mean going forward, what to expect from the preliminary readout in March 2026, and how the 2025 Nobel Prize in Medicine may be linked to Diamyd Medical’s work.
See the interview here
Information presented here are not press releases and may include excerpts from and links to externally published content. Diamyd Medical is not responsible for externally published content.